Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Q2 2019 Earnings Presentation
12 slides from Matinas Biopharma's earnings presentation, Aug 13, 2019
Slide 1: Q2 2019 Investor Update Conference Call
www.matinasbiopharma.com NYSE AMERICAN: MTNB MATINAS BIOPHARMA Q2 2019 Investor Update Conference Call August 13, 2019
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other stat
Slide 3: MAT9001
MAT9O001 BIOPHARMA
Slide 4: MAT9001 Key Highlights
MAT9001 MAT9001 Key Highlights Comparative toxicology Secured supply for all IND Reactivation Completed study (28 Days) completed planned studies through — FDA “May Proceed” ahead of schedule 2020 Letter Received Near-Term Next Steps Bridging Comparative PK Phase 2 Head to Head vs. Vascepa® Crossove
Slide 5: Head to Head Study vs. Vascepa
MAT9001 Head to Head Study vs. Vascepa Phase 2 Comparative Pharmacokinetic and Pharmacodynamic Study to Vascepa * Design * Open-label, randomized, crossover to compare the PK and PD effects of MAT9001 with Vascepa in 70 men and women with elevated triglycerides (Fasting TG 2150 mg/dL to <499 mg/dL)
Slide 6: MAT2203
MAT2203 BIOPHARMA
Slide 7: MAT2203 Key Highlights
MAT2203 MAT2203 Key Highlights Advancing Clinical Development Program in Cryptococcal Meningitis Amphotericin B Broad spectrum Gold standard of treatment for antifungal agent immunocompromised patients NIH funding of Phase 1/2 study of iny~ Positive FDA meeting MAT2203 in Cryptococcal Meningitis | E
Slide 8: EnACT: Phase 1 Safety and Tolerability in Subjects without Active Neuro-Infection
MAT2203 EnACT: Phase 1 Safety and Tolerability in Subjects without Active Neuro-Infection Recruitment of 27 Healthy Subjects ¢ No Meningitis, No Acute Illness e Informed Consent Cohort 1 cAMB Cohort 2 cAMB 1.5g over 24hrs Cohort 3 cAMB 1g over 24hrs 2g over 24hrs n=9 n=9 n=9 * CAMB administered in 4
Slide 9: EnACT: Phase 2A Safety, Tolerability and Efficacy of MAT2203 with 5-FC
Nee MIAT2203. EnACT : Ph 2 safety, tolerability and efficacy of MAT2203 in combo w/ 5-FC in HIV-infected pts w/ crypto Sta i Phase 2A Randomize ¥ 100 participants receiving MAT2203 + flucytosine (5-FC) in 4 stages of escalating durations of MAT2203 and decreasing duration of IV Amphotericin B (AMB)
Slide 10: Key Takeaways
Key Takeaways MAT9001 - initiate comparative PK bridging study in Q4 2019 Patient pre-screening set to commence for head-to-head study vs. Vascepa MAT9001 head-to-head dosing to commence Qi 2020 with topline data expected Q4 2020 QIDP and Fast Track Designation for MAT2203 in treatment of cryptococc
Slide 11: MATINAS
&A MATINAS —————— 11 BIOPHARMA.
Slide 12: MATINAS
www.matinasbiopharma.com MATINAS _$g—_—_—_——— BIOPHARMA
Matinas BioPharma Holdings — Q2 2019 Earnings Presentation on 6ix